FDF

Noscapine Syrup, marketed under the brand name pd NOSCA, is a specialized Finished Dosage Form (FDF) manufactured by Parand Darou Co. Containing 7 mg of Noscapine per 5 ml, this product is a potent non-narcotic antitussive. It acts centrally on the cough center in the medulla oblongata to effectively suppress dry, irritating coughs associated with respiratory infections, the common cold, and bronchitis. Therapeutic Advantages & Accessibility Unlike narcotic cough suppressants, pd...

Methadone Syrup is a key Finished Dosage Form (FDF) manufactured by Parand Darou Co. Formulated with a concentration of 25 mg per 5 ml (equivalent to 5 mg/ml), this product serves as a long-acting synthetic opioid agonist. It is extensively utilized in clinical protocols for Medication-Assisted Treatment (MAT) and the management of Opioid Use Disorder (OUD), providing consistent therapeutic support for addiction rehabilitation. Regulatory Status & Clinical Administration This product is...

Oxycodone FC Tablet is a premium Finished Dosage Form (FDF) and a potent pure opioid agonist manufactured by Parand Darou Co. Engineered for clinical efficacy, Oxycodone acts primarily on central μ-opioid receptors to deliver robust analgesic relief. It is indicated for the management and relief of moderate-to-severe pain, particularly severe post-operative recovery, trauma-induced pain, and persistent oncological (cancer) pain conditions that remain refractory to non-opioid therapeutic alternatives. Therapeutic Strengths, Appearance...

Ibuprofen/Oxycodone FC Tablet, marketed under the brand name Brudon, is a premium Finished Dosage Form (FDF) and a high-potency combination analgesic manufactured by Parand Darou Co. By integrating the anti-inflammatory efficacy of the NSAID Ibuprofen with the centrally acting opioid agonist Oxycodone, this medication provides a multimodal analgesia approach. It is specifically formulated for the clinical management of acute, severe pain, including post-operative recovery (orthopedic and maxillofacial surgeries) and...

Buprenorphine Sublingual Tablet is a specialized Finished Dosage Form (FDF) and a potent partial opioid agonist manufactured by Parand Darou Co. By binding to μ-opioid receptors and exhibiting a distinct "ceiling effect," Buprenorphine serves as a strategic therapeutic agent for both Opioid Use Disorder (OUD) maintenance/substitution therapy and acute or chronic pain management protocols. The sublingual route of administration ensures optimal capillary absorption, bypassing first-pass hepatic metabolism and providing...